Publication | Closed Access

A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors

AngiogenesisGliomaMedicinePharmacologyAdvanced Solid TumorsAnti-cancer AgentOncologyRadiation OncologyTumor MicroenvironmentCancer ResearchNovel Selective InhibitorChinese Patients